The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2020

Filed:

Apr. 21, 2017
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Nathanael S. Gray, Boston, MA (US);

Tinghu Zhang, Brookline, MA (US);

Calla M. Olson, Brookline, MA (US);

Yanke Liang, Brookline, MA (US);

Nicholas Kwiatkowski, Auburn, MA (US);

Baishan Jiang, Watertown, MA (US);

Eric Wang, Jamaica Plain, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 401/14 (2006.01); A61P 37/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07D 401/14 (2013.01); C07D 487/04 (2013.01);
Abstract

The present application provides bifunctional compounds of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6). The present application also relates to methods for the targeted degradation of CDK4 and/or CDK6 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK4 and/or CDK6 which can be utilized in the treatment of disorders modulated by CDK4 and/or CDK6.


Find Patent Forward Citations

Loading…